Skip to content

Knee Osteoarthritis and IPACK

Interspace Between the Popliteal Artery and Capsule of the Posterior Knee-

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06712394
Acronym
IPACK
Enrollment
120
Registered
2024-12-02
Start date
2025-01-01
Completion date
2025-07-01
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Brief summary

Interspace between the Popliteal Artery and Capsule of the posterior Knee (IPACK) block involves ultrasound-guided local anesthetic infiltration of the space between the popliteal artery and the posterior knee joint capsule. The purpose of the study; To investigate the effectiveness of this block applied to knee osteoarthritis in clinical practice. In this study, patients who underwent IPACK block by the practitioner; Demographic data, medications used, block success, block characteristics and block-related complications will be recorded observationally. Before and after the block procedure, patients' pain was measured with the Numeric Rating Scale (NRS) at 1st and 3rd months, their disability levels were measured with The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire and Short Form-12 (Short Form). Quality of life will be measured with the -SF-12) survey.

Interventions

PROCEDUREIPACK

The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.

Sponsors

Sakarya University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients suffering from grade 3 and 4 knee osteoarthritis

Exclusion criteria

* Patients who have had previous knee surgery * Patients who have had any knee injection in the last 3 months * Malignancy * Inflammatory disease * Infectious disease (local or general)

Design outcomes

Primary

MeasureTime frameDescription
Pain assessment1st and 3rd month after the procedureThe Numeric Rating Scale (NRS) is a frequently used tool for assessing and monitoring the severity of pain. The pain scale measures on an 11-point rating system, where 0 indicates the absence of pain and 10 represents the most severe pain one can imagine. Patients are requested to assess their pain on a scale ranging from 0 to 10. The physician obtained from measurements at each visit by directly questioning the patient.
Functional status1st and 3rd month after the procedureThe Western Ontario and McMaster Universities Arthritis Index (WOMAC) is widely used in the evaluation of knee osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: pain, stiffness, and physical function. The questionnaire evaluates activities of daily living and functional mobility. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

Secondary

MeasureTime frameDescription
Quality of life assessment1st and 3rd month after the procedureThe assessment of quality of life was conducted using the SF-12, a questionnaire specifically designed to measure health-related quality of life. The SF-12 consists of twelve items that evaluate eight different health domains, providing an evaluation of both physical and mental well-being. The SF-12 provides two summary scores: the mental component score (MCS-12) and the physical component score (PCS-12). A decrease in the questionnaire score indicates progression of disability. The questionnaire's validity and reliability were ensured, and the Turkish version of the questionnaire was filled out by the patients.

Contacts

Primary ContactAli eman
dralieman02@gmail.com+905325152816

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026